The launch of a generic version of long-awaited complex blockbuster drug, Glatiramer Acetate in the USA market has catapulted the company to the next orbit in terms of its capability and credibility as a niche player in pharmaceutical sector.
The successful launch of this long gestation product underscores the Company’s tenacity and focus on ‘difficult to manufacture’ molecules.
Natco through its marketing partner, Mylan NV launched the first generic version of Glatiramer Acetate, 40 mg in the USA in October, 2017. The drug has brand market value of $3.64 billion for 12 months ending July 31st 2017, according to Quintiles IMS.
